Navigation Links
Doubling down against diabetes
Date:11/13/2012

This press release is available in German.

A collaboration between scientists in Munich, Germany and Bloomington, USA may have overcome one of the major challenges drug makers have struggled with for years: Delivering powerful nuclear hormones to specific tissues, while keeping them away from others.

The teams led by physician Matthias Tschp (Helmholtz Zentrum Mnchen, and Technische Universitt Mnchen) and chemist Richard DiMarchi (Indiana University) used natural gut peptides targeting cell membrane receptors and engineered them to carry small steroids known to act at the cell nucleus. DiMarchi and Tschp hoped that such "turbo-charged" hormone hybrids would only deliver their steroid inside cells, where their specific peptide receptor was expressed at the surface.

Both teams had been working together for years to discover new ways to treat obesity and diabetes. They therefore started out with the gut hormone glucagon-like peptide-1, which is known to act at pancreas and brain cells to improve insulin secretion, blood glucose, and body weight. They engineered these peptides to reversibly bind the female sex steroid, estrogen, which is also known to confer powerful metabolic benefits at some of the same target cells. In the past, pharmacologists had been unable to utilize such benefits as high doses of systemic estrogen can also powerfully affect reproductive organs and increase cancer risk.

Using their GLP-1/estrogen-conjugates however, DiMarchi and Tschp found that they were able to multiply metabolic benefits in mice, without apparent side effects on estrogen-sensitive reproductive organs such as the uterus. They also found no impact of their "turbo-charged" gut peptides on growth of estrogen-sensitive tumors. Genetic studies at the same time however uncovered clear estrogen effects in pancreas and brain tissue of mice treated with the new combination drug candidate, indicating that the collaborating teams had indeed succeeded with targeted delivery of steroids.

"Our novel GLP-1/estrogen molecules seem to outperform more traditional therapeutics in mouse models of obesity and type 2 diabetes" says Brian Finan, scientist at the Helmholtz Zentrum Mnchen and first author of the study published online in the journal Nature Medicine. "What we are even more excited about" he adds "is the opportunity to use targeted steroid hormone for other diseases, where side effects had prevented therapeutic use in the past. "There is still a lot we don't know about the mechanistic details," cautions Matthias Tschp, director of the Helmholtz Institute for Diabetes and Obesity "but if they proof safe enough for clinical use, these molecules could offer transformative potential."


'/>"/>

Contact: Tina Heun-Rattei
Heun@zv.tum.de
Technische Universitaet Muenchen
Source:Eurekalert

Related medicine news :

1. Doubling down on heart failure: Researchers discover new route to disease, and drugs to match
2. Scientists identify major source of cells defense against oxidative stress
3. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
4. Will women use microbicides to protect themselves against HIV?
5. Vitamin E in diet protects against many cancers
6. Lower-Dose Radioiodine Effective Against Thyroid Cancer
7. Study identifies possible protective blood factors against Type 2 diabetes
8. Stem Cell Study Shows Promising Results Against Heart Failure
9. Blood pressure drugs dont protect against colorectal cancer
10. CNIO scientists successfully test the first gene therapy against aging-associated decline
11. Vitamin D + TB vaccine: Allies in fight against bladder cancer?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. ... Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at an early ... medicine is about more than making diagnoses and prescribing medicine,” he states. “It is ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... inspirational interview of two ostomy patients, standing as living proof that attitude and ... from digestive diseases and issues that spike around the holidays. This campaign will ...
(Date:12/2/2016)... ... , ... More than half of American teens report losing their virginity before ... their child about sex related topics, less than 60 percent spoke about deeper themes ... the launch of its second edition of the “Sexual Wellness” campaign, aiming to address ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, ... entry through labeling, storing, shipping and disposal. The new version is a faster ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, Inc. ... the first company to offer robotic imaging to veterinary medicine is sponsoring the ... 941 for the American Association of Equine Practitioners 62nd Annual Convention from December ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... December 2, 2016 Orthopedic Implants (Including ... is Expected to Gain a Significant Market Share Owing to ... ... According to a new report ... Implants Sterile Packaging: Clamshell Product Type Segment Projected to Witness ...
(Date:12/2/2016)... Dec. 2, 2016   CytoSorbents Corporation (NASDAQ: ... its European Union approved CytoSorb ® cytokine adsorber ... patients worldwide, announced that Dr. Phillip Chan , ... Annual LD Micro Main Event investor conference held ... the Luxe Sunset Boulevard Hotel in Los ...
(Date:12/2/2016)... 2, 2016 On Thursday, the NASDAQ ... Dow Jones Industrial Average edged 0.36% higher, to finish at ... Losses were broad based as six out of nine sectors ... reports on the following Services equities: Myriad Genetics Inc. (NASDAQ: ... ), INC Research Holdings Inc. (NASDAQ: INCR ), ...
Breaking Medicine Technology: